---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028093"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2024-07-17T23:59:59+00:00"
generated_at: "2026-05-31T20:12:02.426509+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Processa appoints Russell Skibsted as CFO; James Stanker retires

## Summary
- Russell Skibsted appointed CFO effective July 16, 2024; succeeds James Stanker who retired.
- Skibsted brings 30 years of pharma finance experience; most recently CFO of Alimera Sciences.
- Annual base salary $400,000; eligible for 35% target bonus and 28,000 RSUs upon goal achievement.
- Stanker remains part-time employee during transition period.

## SEC filing metadata
- accession: 0001493152-24-028093
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2024-07-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/0001493152-24-028093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028093
- JSON: https://secwatch.observer/filing/0001493152-24-028093.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028093.txt

## Key facts
- Executive change
  James Stanker resigned as Chief Financial Officer at Processa Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: by mutual agreement, James Stanker resigned as Chief Financial Officer of the Company, effective July 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/0001493152-24-028093-index.htm
- Executive change
  Russell Skibsted was appointed as Chief Financial Officer at Processa Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: announced the appointment of Mr. Russell Skibsted, Effective July 16, 2024 as its Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/0001493152-24-028093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.